Results for trombembolične translation from Slovenian to English

aktivne trombembolične motnje
active thromboembolic disorders

tveganje za trombembolične dogodke
thromboembolic risk:

dejavniki tveganja za trombembolične motnje (glejte spodaj);
risk factors for thromboembolic disorders (see below)

tveganje za trombembolične dogodke (rt 1, 67, 95% iz:
an increased relative risk of thromboembolic events (rr 1.67, 95% ci:

seznanitev bolnikov o kronični bolezni jeter in tveganju za trombembolične dogodke.
educate patients about chronic liver disease and the risk of thromboembolic events.

to ni povezano s kakršnimkoli povečanjem trombembolične umrljivosti v primerjavi s kontrolnimi skupinami.
32 the incidences of undesirable effects in clinical trials, considered related to treatment with neorecoromon are shown in the table below.

bolniki z velikim tveganjem umrljivosti med operacijo in intrinzičnimi dejavniki tveganja za trombembolične dogodke
patients at high surgical mortality risk and with intrinsic risk factors for thromboembolic events

vendar moramo upoštevati, da nosečnost sama in tudi ohss prinašata povečano tveganje za trombembolične dogodke.
it should be noted however that pregnancy itself as well as ohss also carry an increased risk of thromboembolic events.

tveganje za arterijske trombembolične zaplete se pri ženskah, ki uporabljajo kombinirane kontraceptive, povečuje s:
the risk of arterial thromboembolic complications in combined contraceptives users increases with:

bolniki, pri katerih obstaja med operacijo veliko tveganje smrti in ki imajo intrinzične dejavnike tveganja za trombembolične dogodke
patients at high surgical mortality risk and with intrinsic risk factors for thromboembolic events

necitumumaba se ne sme dati bolnikom z več dejavniki tveganja za trombembolične dogodke, razen če koristi odtehtajo tveganja za bolnika.
necitumumab should not be administered to patients with multiple risk factors for thromboembolic events unless the benefits outweigh the risks to the patient.

po dajanju zdravil s faktorjem ix je prisotno morebitno tveganje za trombembolične epizode, z večjim tveganjem pri zdravilih z manjšo čistoto.
there is a potential risk of thromboembolic episodes following the administration of factor ix products, with a higher risk for low purity preparations.

zelo redko: trombembolične reakcije, kot so miokardni infarkt, možganska kap, pljučna embolija in globoka venska tromboza.
thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism and deep vein thromboses.

vendar pa je treba opomniti, da nosečnost sama po sebi in ohss zvečujeta tveganje za trombembolične dogodke kot so pljučna embolija, ishemična kap ali miokardni infarkt.
it should be noted, however, that pregnancy itself as well as ohss also carry an increased risk of thromboembolic events, such as pulmonary embolism, ischaemic stroke or myocardial infarction.

tveganje za arterijske trombembolične zaplete ali cerebrovaskularni dogodek je med uporabnicami chc večje pri ženskah z dejavniki tveganja (glejte preglednico).
the risk of arterial thromboembolic complications or of a cerebrovascular accident in chc users increases in women with risk factors (see table).

pri odmerku 220 mg so bili izidi boljši, saj je bila točkovna ocena za večje trombembolične dogodke nekoliko boljša kot pri enoksaparinu (preglednica 10).
better results were seen with the 220 mg dose where the point estimate of major vte was slightly better than enoxaparin (table 10).

zelo redko: s transfuzijo povezana akutna okvara pljuč in trombembolične reakcije, kot so miokardni infarkt, možganska kap, pljučna embolija in globoka venska tromboza.
very rarely: transfusion related acute lung injury and thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism and deep vein thromboses.

klinična ocena lahko razkrije hipovolemijo, hemokoncentracijo, elektrolitsko neravnovesje, ascites, hemoperitonej, plevralni izliv, hidrotoraks ali akutno respiratorno stisko in trombembolične dogodke.
clinical evaluation may reveal hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural effusions, hydrothorax, or acute pulmonary distress, and thromboembolic events.

pri bolnikih, zdravljenih z rekombinantnim humanim eritropoetinom, so ugotovili večje relativno tveganje za trombembolične dogodke (rt 1, 67, 95% iz:
an increased relative risk of thromboembolic events (rr 1.67, 95% ci:

razlika v antitrombocitni aktivnosti med nekaterimi nsaid, ki zavirajo cox-1, in selektivnimi zaviralci cox-2 bi lahko bila klinično pomembna pri bolnikih, ki jih ogrožajo trombembolične reakcije.
the difference in antiplatelet activity between some cox-1 inhibiting nsaids and cox-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions.